Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019
Scott Canna, Grant S. Schulert, Adriana de Jesus, Alex Pickering, Hermine I. Brunner, Massimo Gadina, Stewart J. Levine, Raphaela Goldbach‐Mansky, Jonathan Boutelle, Rashmi Sinha, Fabrizio De Benedetti, Alexei A. Grom, on behalf of the NextGen 2019 Participants, Beth S. Gottlieb, Rae S. M. Yeung, Mona Riskalla, Sampath Prahalad, Sara Alehashemi, Shan Chandrakasan, Sebastiaan J. Vastert, Yuki Kimura, Anna R. Carlson, Emily Schumacher, Regina Minerva, Jonathan D. Pierce, Kate Pierce, Zulayka Martinez, Kari Cupp, Leah Bush, Wendy Costello, Vincent Del Gaizo
Abstract
For reasons poorly understood, and despite the availability of biological medications blocking IL-1 and IL-6 that have markedly improved overall disease control, children with Systemic Juvenile Idiopathic Arthritis (SJIA) are now increasingly diagnosed with life-threatening chronic complications, including hepatitis and lung disease (SJIA-LD). On October 3-4, 2019, a two-day meeting, NextGen Therapies for Systemic Juvenile Idiopathic Arthritis (SJIA) & macrophage activation syndrome (MAS) organized by the Systemic JIA Foundation ( www.systemicjia.org/ ) in Washington, DC brought together scientists, clinicians, parents and FDA representatives with the objectives (1) to integrate clinical and research findings in MAS and SJIA-LD, and (2) to develop a shared understanding of this seemingly new pulmonary complication of SJIA. The current manuscript summarizes discussions and conclusions of the meeting.